Unicycive Signs up to $130M Financing to Commercialize and Launch Renazorb IND

(24/7 MARKET NEWS) – Unicycive Therapeutics, Inc. (NASDAQ: UNCY) stated, this morning, that it signed a securities purchase agreement that will provide up to $130 million in gross proceeds to Unicycive through a private placement that includes initial upfront funding of $30 million.

Unicycive is at $1.06, up $0.57 (+116.33%), on 3.3 million premarket shares.

Its 52-week trading range is $0.4004 to $1.64. If it can clear the $1.15, on strong volume, it may try to retrace to the $1.25 and $1.50 levels.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist